New drugs that spur weight loss and deal with diabetes have been having the general public—as well as the pharmaceutical industry—by storm. The latest entrant, Zepbound, a short while ago joined Ozempic, Wegovy, Victoza and Other folks in a rising course of medications termed GLP-one receptor agonists.(Off-label drug use is when an FDA-accepted